Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Aug
04
Today In Oncology
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
AI-Based cfDNA Fragmentome Classifier May Improve Detection of HCC
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo